Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia-Reference-Cited by-同舟云学术

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Published:2021-01-01 Issue:1 Volume:9 Page:
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Kansal Anuraag R.¹,Reifsnider Odette S.¹,Brand Sarah B.¹,Hawkins Neil²,Coughlan Anna¹,Li Shujun¹,Cragin Lael¹,Paramore Clark³,Dietz Andrew C.³,Caro J. Jaime¹^ORCID

Affiliation:

1. Evidera, Inc., Waltham, MA, USA

2. Visible Analytics, Oxford, UK

3. Bluebird Bio, Cambridge, MA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20016689.2021.1922028

Reference59 articles.

1. Increasing prevalence of thalassemia in America: Implications for primary care

2. Centers for Disease Control and Prevention. Thalassemia awareness. 2019 cited 2019 Jun 24]; Available from: https://www.cdc.gov/features/international-thalassemia/index.html.

3. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel

4. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010

5. Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

2. Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States;PharmacoEconomics;2024-04-29

3. A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges?;International Journal of Technology Assessment in Health Care;2024

4. Betibeglogene Autotemcel; A new hope for transfusion dependent beta-thalassaemia;Journal of the Pakistan Medical Association;2023-09-13

5. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States;Journal of Market Access & Health Policy;2023-05-26